184944-87-4

Basic information

• Product Name: CHEMBRDG-BB 7949765
• Synonyms: CHEMBRDG-BB 7949765;3-[2-(4-MORPHOLINYL)-2-OXOETHOXY]ANILINE;CBI-BB ZERO/006512;UKRORGSYN-BB BBV-099906;[3-(2-morpholin-4-yl-2-oxoethoxy)phenyl]amine;3-(2-morpholin-4-yl-2-oxoethoxy)aniline;3-[2-(4-morpholinyl)-2-oxoethoxy]aniline(SALTDATA: FREE);2-(3-aminophenoxy)-1-morpholin-4-ylethanone
• CAS NO: 184944-87-4
• Molecular Formula: C₁₂H₁₆N₂O₃
• Molecular Weight: 236.269
• Mol File: 184944-87-4.mol

Chemical Properties

• Boiling Point: 485.2°C at 760 mmHg
• Flash Point: 247.3°C
• Appearance: /
• Density: 1.24g/cm³
• Vapor Pressure: 1.44E-09mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: CHEMBRDG-BB 7949765(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 7949765(184944-87-4)
• EPA Substance Registry System: CHEMBRDG-BB 7949765(184944-87-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 184944-87-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CHEMBRDG-BB 7949765 is used as a versatile intermediate for the synthesis of various pharmaceutical products. Its unique structure and reactivity make it a promising candidate for the development of novel drugs and chemical processes.
Used in Agrochemical Industry:
CHEMBRDG-BB 7949765 is used as a reagent in the preparation of various agrochemical products. Its diverse chemical properties and applications make it a valuable component in the development of new agrochemicals.
Used in Organic Synthesis:
CHEMBRDG-BB 7949765 is used as a building block for the synthesis of various biologically active molecules. Its unique structure and reactivity make it a valuable component in the development of new organic compounds and chemical processes.

InChI:InChI=1/C12H16N2O3/c13-10-2-1-3-11(8-10)17-9-12(15)14-4-6-16-7-5-14/h1-3,8H,4-7,9,13H2

Upstream product

• 50508-38-8 4-[(3-nitro-phenoxy)-acetyl]-morpholine 
• 554-84-7 meta-nitrophenol 
• 138563-69-6 tert-butyl 2-(3-nitrophenoxy)acetate 
• 1878-88-2 2-(3-nitrophenoxy)acetic acid 
• 5544-77-4 2-(3-nitrophenoxy)-acetic acid ethyl ester 
• 40257-02-1 3-nitrophenoxyacetyl chloride 
• 1025941-26-7 1-Imidazol-1-yl-2-(3-nitro-phenoxy)-ethanone 

Relevant articles and documents

GLYCINE B ANTAGONISTS

The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides inhibitors of protein kinases of formula I-a and I-b, pharmaceutically acceptable compositions thereof, and methods of using the same.

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent

Analogs of the previously reported 1,5-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonist 1 were prepared which explore substitution and/or replacement of the C-3 phenyl urea moiety. Agonist efficacy on the isolated guinea pig gallbladder (GPGB) was retained with a variety of substituted ureas and amide analogs. Three compounds were identified which were orally active in the mouse gallbladder emptying assay (MGBE). The 2-indolamide (52) and N-(carboxymethyl)-2-indolamide (54) derivatives had improved affinity for the human CCK-A receptor but reduced agonist efficacy on the GPGB. Neither indolamide was orally active in a rat feeding assay. In contrast, the (3-carboxyphenyl)urea derivative (29, GW7854) had moderately increased affinity for the human CCK-B receptor but was a potent full agonist on the GPGB and was orally active in both the MGBE and rat feeding assays. GW7854 was a full agonist (EC50 = 60 nM) for calcium mobilization on CHO K1 cells expressing hCCK-A receptors and a potent antagonist of CCK-8 (pA2 = 9.1) on CHO K1 cells expressing hCCK-B receptors. GW7854 is a potent mixed CCK-A agonist/CCK-B antagonist which is orally active in two in vivo models of CCK-A-mediated agonist activity.